The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
As of Friday's close, AstraZeneca's stock was down 6.6% since the start of 2024 and about 1.85% over the last 12 months. WHAT TO WATCH --PIPELINE: Market watchers will closely monitor the potential of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback